Eli Lilly LLY Collaboration and Other Revenue — Revenue

Similar metrics at other companies

CYTKCollaboration Revenues — Revenue

$3.29M+36.2%

ASPICollaboration Revenue — Revenue

$200K—

NRIXCollaboration revenue — Revenue

$9.04M-35.7%

PLUSCollaboration — Revenue

$10.18M+24.1%

CSCOCollaboration — Revenue

$1.02B-0.7%

RXSTLicense And Collaboration Revenue — Revenue

$6.5M—

FAQ

What is Eli Lilly's collaboration and other revenue — revenue?

Eli Lilly (LLY) reported collaboration and other revenue — revenue of $1.57B in Q2 2026.

How has Eli Lilly's collaboration and other revenue — revenue changed year-over-year?

Eli Lilly's collaboration and other revenue — revenue increased by 88.8% year-over-year, from $832M to $1.57B.

What is the long-term trend for Eli Lilly's collaboration and other revenue — revenue?

Over 4 years (2021 to 2025), Eli Lilly's collaboration and other revenue — revenue has grown at a 15.6% compound annual growth rate (CAGR), from $2.36B to $4.22B.

What does collaboration and other revenue — revenue mean?

This metric represents revenue generated through strategic partnerships, licensing agreements, and other non-core product sales activities. It captures income streams derived from co-development or co-promotion arrangements with other pharmaceutical entities, as well as royalties or milestone payments. This category is essential for understanding the company's ability to monetize its intellectual property and research pipeline through external alliances.